EMA has published a concept paper about the need for guidance to inform the development of systemic sclerosis (SSc) treatments. They have identified study designs & endpoints; exploratory and confirmatory trials, and assessments of safety and efficacy. See draft here: https://t.co/WADBrw2uXe

SCLERODERMA Pt education page from JAMA Dermatology https://t.co/hILqCeUnE2 https://t.co/cZCgoRHbDZ

Persistent Burden in Early RA Despite Disease Control: insights from CareRA Trials Advances in the treatment of rheumatoid arthritis (RA), particularly the treat-to-target strategy and the introduction of effective disease-modifying antirheumatic drugs (DMARDs), have improved https://t.co/cMiF6POKGS

Global burden of dz study - UN statistics show post-Menopausal women (PMW) are 20% of all women in 2021 (vs 13.7% 1990). From 1990 to 2021, the prevalence of MSK Dz in PMW significantly risen, especially for RA, OA, and gout. https://t.co/HdkopkxLdv https://t.co/wsGhg0P1tL

A new mechanism of action in SARD-ILD Nerandomilast, an inhibitor of phosphodiesterase 4B, orally administered, is a new mechanism of action to treat lung fibrotic diseases. FIBRONEER-ILD, the Phase 3 RCT of Nerandomilast in patients with progressive pulmonary fibrosis, was https://t.co/goikCwJa2x

Survey of 154 Saudi established #RA pts on MTX >3mos; 64% claiming #MTX intolerance & 36% w/ MTX Intolerance Severity Score (MISS) >6. But MTX intolerance was NOT related to dose or route of administration, meal or time of day. These were not new MTX starters https://t.co/6KWGcZvx4o

Why is RA Difficult to Treat? Dr. Jonathan Kay shares his perspective on five posters presented at EULAR 2025 in Barcelona, Spain. Posters reviewed: POS0027, POS0028, POS0185, POS0030, POS0163 https://t.co/Ad4hVN21MJ https://t.co/d0BfQWjjL0

FDA has approved a SC autoinjector of Benlysta (BEL) for use in pediatric lupus nephritis & pts > 5rs of age for SLE and active LN. BEL SC dosing for Pediatric SLE: 200 mg qwk (>40 kg) or 200 mg EOW (q2wk) if 15-40 kg. https://t.co/xrMJUgdSWv https://t.co/UJ2LZ3dU5p

Difficult to Treat Psoriatic Arthritis Dr. Eric Ruderman shares his perspectives on data being presented at the 2025 EULAR meeting in Barcelona, Spain. https://t.co/AdKILLc12Y https://t.co/4pB0OH2Gup

Does Abatacept Buy You Time Off RA? Dr. David Liew reports on abstract OP0325 presented at the 2025 EULAR meeting in Barcelona, Spain. https://t.co/t8NLvPjcju https://t.co/bloTKQ87rv

Not All About B Cells: Myeloid Related Inflammation in Lupus Pathogenesis Dr. Andrea Fava shares his perspectives from the EULAR 2025 meeting in Barcelona, Spain. https://t.co/8Lh02c3sy4 https://t.co/XX7wKovD9u